Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples
Shanghai Henlius Biotech, Inc. (HKG: 2696) released its first-half 2026 results, reporting total revenue of...
HKG: 2696
Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has entered into a strategic collaboration...
Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon Canada announced the official commercial launch of...
Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX3902 Trispecific Antibody in Advanced Solid Tumors
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...
Shanghai Henlius Biotech’s HLX04-O Meets Primary Endpoints in Phase III Trial for Wet AMD, Demonstrating Non-Inferiority to Ranibizumab
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Phase III international multicenter clinical study...
Henlius Biotech’s Serplulimab Becomes World’s First PD-1 Inhibitor Approved for Perioperative Gastric Cancer Treatment Following Landmark Phase III Results
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...
Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in the...
Henlius Biotech’s Perjeta Biosimilar HLX11 (Poherdy) Secures NMPA Approval for HER2-Positive Breast Cancer in China
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has...
Henlius Biotech Initiates China Dosing in Phase II/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in China for an...
Shanghai Henlius Biotech Initiates Phase II/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a...
Shanghai Henlius Biotech Doses First Patient in China for Global Phase I Study of Daratumumab Biosimilar HLX15-SC in Multiple Myeloma
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in China...
Henlius Biotech’s PD-1 Inhibitor Hetronifly Receives CHMP Recommendation for Squamous NSCLC in EU
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the European Medicines Agency’s Committee for Medicinal...
Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that Australia’s Therapeutic Goods Administration (TGA) has granted...
Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...
Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a strategic partnership with fellow Chinese biopharmaceutical company...
Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory approval from Australia’s Therapeutic...
Shanghai Henlius Biotech Doses First Patient in Phase I Trial of HLX97 – Novel KAT6A/B Inhibitor for Advanced Solid Tumors
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a...
Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor
Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has secured two additional indication approvals from...
Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance...
Henlius Biotech Secures European Commission Approval for Poherdy Biosimilar to Roche’s Perjeta
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced it has received marketing authorization from the European...